Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025

Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin have announced that full data from the pivotal KOMET-001 trial of their investigational menin inhibitor, ziftomenib, will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Ziftomenib, a once-daily oral therapy, is the first investigational drug to receive Breakthrough Therapy Designation from the FDA for relapsed/refractory NPM1-mutant acute myeloid leukemia (AML), a mutation present in about 30% of AML cases with no approved targeted therapies.

Kura Oncology, Inc. (NASDAQ:KURA) and Kyowa Kirin Announce Promising Ziftomenib Data to Be Presented at ASCO 2025 for NPM1-Mutant AML

A doctor examining a patient’s x-ray in a laboratory, showing the capabilities of the company’s oncology therapies.

The KOMET-001 trial achieved its primary endpoint, demonstrating statistically significant rates of complete remission and partial hematological recovery. Ziftomenib also showed a favorable safety profile, with limited myelosuppression and only 3% of patients discontinuing due to side effects. Kura Oncology, Inc. (NASDAQ:KURA)’s CEO, Dr. Troy Wilson, emphasized the drug’s potential as a new treatment option for this difficult-to-treat AML subgroup and reaffirmed the company’s commitment to advancing ziftomenib toward commercialization.

Additionally, a poster on the ongoing KOMET-015 trial will be presented at ASCO. Detailed data and session information are now available on the ASCO website, with further results to be revealed at the meeting.

While we acknowledge the potential of KURA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk.  If you are looking for an AI stock that is more promising than KURA and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.

Disclosure: None.